HIKAL Stock Overview
Manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Hikal Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹393.00 |
| 52 Week High | ₹416.95 |
| 52 Week Low | ₹260.30 |
| Beta | 1.25 |
| 11 Month Change | 3.71% |
| 3 Month Change | 20.11% |
| 1 Year Change | 45.69% |
| 33 Year Change | -25.94% |
| 5 Year Change | 254.37% |
| Change since IPO | 2,604.13% |
Recent News & Updates
Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results
Nov 15
Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%
Sep 13We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope
Sep 11Recent updates
Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results
Nov 15Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%
Sep 13We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope
Sep 11Hikal Limited's (NSE:HIKAL) Popularity With Investors Is Clear
Jun 12A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)
Jun 03Is Hikal (NSE:HIKAL) Using Too Much Debt?
Mar 28Hikal (NSE:HIKAL) Is Reducing Its Dividend To ₹0.60
Feb 07A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)
Dec 08Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)
Sep 16Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)
Mar 18Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20
Feb 16Is Hikal (NSE:HIKAL) Using Too Much Debt?
Jan 13With EPS Growth And More, Hikal (NSE:HIKAL) Is Interesting
Jun 01We Think Hikal (NSE:HIKAL) Can Stay On Top Of Its Debt
May 17An Intrinsic Calculation For Hikal Limited (NSE:HIKAL) Suggests It's 25% Undervalued
Mar 23Does Hikal Limited (NSE:HIKAL) Have A Place In Your Dividend Portfolio?
Mar 10If You Like EPS Growth Then Check Out Hikal (NSE:HIKAL) Before It's Too Late
Feb 23Be Sure To Check Out Hikal Limited (NSE:HIKAL) Before It Goes Ex-Dividend
Feb 10Shareholder Returns
| HIKAL | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.2% | -3.1% | -3.4% |
| 1Y | 45.7% | 41.1% | 27.0% |
Return vs Industry: HIKAL exceeded the Indian Pharmaceuticals industry which returned 41.1% over the past year.
Return vs Market: HIKAL exceeded the Indian Market which returned 27% over the past year.
Price Volatility
| HIKAL volatility | |
|---|---|
| HIKAL Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: HIKAL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HIKAL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 2,061 | Sameer Hiremath | www.hikal.com |
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs).
Hikal Limited Fundamentals Summary
| HIKAL fundamental statistics | |
|---|---|
| Market cap | ₹48.36b |
| Earnings (TTM) | ₹736.02m |
| Revenue (TTM) | ₹18.21b |
65.7x
P/E Ratio2.7x
P/S RatioIs HIKAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIKAL income statement (TTM) | |
|---|---|
| Revenue | ₹18.21b |
| Cost of Revenue | ₹9.02b |
| Gross Profit | ₹9.20b |
| Other Expenses | ₹8.46b |
| Earnings | ₹736.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.97 |
| Gross Margin | 50.50% |
| Net Profit Margin | 4.04% |
| Debt/Equity Ratio | 64.2% |
How did HIKAL perform over the long term?
See historical performance and comparison